Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelin
Abstract Cell surface mesothelin (MSLN) can be solubilized and released into the systemic circulation. The resulting soluble MSLN (sMSLN) may interfere with therapies targeting surface MSLN. We investigated the effects of sMSLN on anetumab, an antibody-based therapy against MSLN, anetumab ravtansine...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-04-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-97952-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850156591591981056 |
|---|---|
| author | Katherine E. R. Smith Jennifer R. Ayers-Ringler Jacob J. Orme Fabrice Lucien Yohan Kim Jeffrey L. Winters Aaron S. Mansfield |
| author_facet | Katherine E. R. Smith Jennifer R. Ayers-Ringler Jacob J. Orme Fabrice Lucien Yohan Kim Jeffrey L. Winters Aaron S. Mansfield |
| author_sort | Katherine E. R. Smith |
| collection | DOAJ |
| description | Abstract Cell surface mesothelin (MSLN) can be solubilized and released into the systemic circulation. The resulting soluble MSLN (sMSLN) may interfere with therapies targeting surface MSLN. We investigated the effects of sMSLN on anetumab, an antibody-based therapy against MSLN, anetumab ravtansine, an antibody drug conjugate, and mechanisms to decrease sMSLN. Whole blood samples were collected before and after one plasma volume of therapeutic plasma exchange (TPE). sMSLN levels were measured with ELISA assays in matched pre- and post-TPE plasma samples, and anetumab-immunoprecipitated samples. We also used protease inhibitors (PIs) as a mechanism to stabilize surface MSLN, then evaluated the cytotoxic effects of anetumab ravtansine. Our findings indicate that sMSLN sequesters and may impair the efficacy of this anti-MSLN antibody based on results showing that anetumab decreases the concentration of MSLN in plasma (p < 0.05) and reduced cytotoxicity of anetumab ravtansine in the presence of recombinant MSLN in cell lines, a surrogate for sMSLN. TPE consistently reduced sMSLN (p < 0.05) with an average decrease of 43.6% (15.4 ng/mL). Surface MSLN stabilization was inconsistently observed with PIs. Overall, sMSLN could represent a predictive biomarker for MSLN directed therapies. TPE may be more reliable than PIs to reduce sMSLN and ultimately restore sensitivity to these therapies in patients with high sMSLN. |
| format | Article |
| id | doaj-art-9346d6f1b9d9468ea265fb0c60017604 |
| institution | OA Journals |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-9346d6f1b9d9468ea265fb0c600176042025-08-20T02:24:29ZengNature PortfolioScientific Reports2045-23222025-04-011511910.1038/s41598-025-97952-xEvaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelinKatherine E. R. Smith0Jennifer R. Ayers-Ringler1Jacob J. Orme2Fabrice Lucien3Yohan Kim4Jeffrey L. Winters5Aaron S. Mansfield6Medical Oncology, Mayo ClinicMedical Oncology, Mayo ClinicMedical Oncology, Mayo ClinicDepartment of Urology, Mayo ClinicDepartment of Urology, Mayo ClinicDivision of Transfusion Medicine, Mayo ClinicMedical Oncology, Mayo ClinicAbstract Cell surface mesothelin (MSLN) can be solubilized and released into the systemic circulation. The resulting soluble MSLN (sMSLN) may interfere with therapies targeting surface MSLN. We investigated the effects of sMSLN on anetumab, an antibody-based therapy against MSLN, anetumab ravtansine, an antibody drug conjugate, and mechanisms to decrease sMSLN. Whole blood samples were collected before and after one plasma volume of therapeutic plasma exchange (TPE). sMSLN levels were measured with ELISA assays in matched pre- and post-TPE plasma samples, and anetumab-immunoprecipitated samples. We also used protease inhibitors (PIs) as a mechanism to stabilize surface MSLN, then evaluated the cytotoxic effects of anetumab ravtansine. Our findings indicate that sMSLN sequesters and may impair the efficacy of this anti-MSLN antibody based on results showing that anetumab decreases the concentration of MSLN in plasma (p < 0.05) and reduced cytotoxicity of anetumab ravtansine in the presence of recombinant MSLN in cell lines, a surrogate for sMSLN. TPE consistently reduced sMSLN (p < 0.05) with an average decrease of 43.6% (15.4 ng/mL). Surface MSLN stabilization was inconsistently observed with PIs. Overall, sMSLN could represent a predictive biomarker for MSLN directed therapies. TPE may be more reliable than PIs to reduce sMSLN and ultimately restore sensitivity to these therapies in patients with high sMSLN.https://doi.org/10.1038/s41598-025-97952-xSoluble mesothelinMesotheliomaSoluble oncogenic proteinsTherapeutic plasma exchangeProtease inhibitors |
| spellingShingle | Katherine E. R. Smith Jennifer R. Ayers-Ringler Jacob J. Orme Fabrice Lucien Yohan Kim Jeffrey L. Winters Aaron S. Mansfield Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelin Scientific Reports Soluble mesothelin Mesothelioma Soluble oncogenic proteins Therapeutic plasma exchange Protease inhibitors |
| title | Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelin |
| title_full | Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelin |
| title_fullStr | Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelin |
| title_full_unstemmed | Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelin |
| title_short | Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelin |
| title_sort | evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelin |
| topic | Soluble mesothelin Mesothelioma Soluble oncogenic proteins Therapeutic plasma exchange Protease inhibitors |
| url | https://doi.org/10.1038/s41598-025-97952-x |
| work_keys_str_mv | AT katherineersmith evaluatingtherapeuticplasmaexchangeandproteaseinhibitorsasmechanismstoreducesolublemesothelin AT jenniferrayersringler evaluatingtherapeuticplasmaexchangeandproteaseinhibitorsasmechanismstoreducesolublemesothelin AT jacobjorme evaluatingtherapeuticplasmaexchangeandproteaseinhibitorsasmechanismstoreducesolublemesothelin AT fabricelucien evaluatingtherapeuticplasmaexchangeandproteaseinhibitorsasmechanismstoreducesolublemesothelin AT yohankim evaluatingtherapeuticplasmaexchangeandproteaseinhibitorsasmechanismstoreducesolublemesothelin AT jeffreylwinters evaluatingtherapeuticplasmaexchangeandproteaseinhibitorsasmechanismstoreducesolublemesothelin AT aaronsmansfield evaluatingtherapeuticplasmaexchangeandproteaseinhibitorsasmechanismstoreducesolublemesothelin |